Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination
- PMID: 33641230
- DOI: 10.1111/liv.14843
Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination
Abstract
Hepatitis B is an eminent risk factor for hepatocellular carcinoma (HCC) in Southeast Asia and sub-Saharan Africa, whereas hepatitis C is a key risk factor for HCC in Western Europe and North America. Increased awareness of the global burden of viral hepatitis resulted, in May 2016, in the adoption of the first global health sector strategy on viral hepatitis by the World Health Assembly, which calls for the elimination of viral hepatitis as a public health threat by 2030. Although the incidence of liver cancer resulting from viral infections has increased since the 1990s, the implementation of public health interventions, such as hepatitis B vaccination and antiviral therapies might have reduced the global burdens of HCC. Hepatitis B immunization in infancy has been associated with a reduction in the risk of infant fulminant hepatitis, chronic liver disease, and HCC in Taiwan. Achieving viral hepatitis elimination by 2030 can be accelerated by improving the access to HCC screening programs. HCC surveillance programs in developed countries must be refined to increase an access to personalized surveillance program, whereas the limited access to surveillance and treatment of HCC in developing countries remains a significant public health issue.
Keywords: World Health Organization; epidemiology; hepatitis B; hepatitis C; hepatocellular carcinoma; surveillance.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Comment in
-
Post hepatitis B-eliminated hepatocellular carcinoma: New challenges.Liver Int. 2021 May;41(5):1173-1174. doi: 10.1111/liv.14878. Epub 2021 Mar 22. Liver Int. 2021. PMID: 33719182 No abstract available.
References
REFERENCES
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
-
- Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(9):1485-1491.
-
- Cancer Epidemiology and Prevention. Fourth Edition, New to This Edition. Oxford, NY: Oxford University Press; 2017:1328.
-
- de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180-e190.
-
- Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 2017;3(12):1683-1691.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical